14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
PYPD vs CNTB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Connect Biopharma Holdings Limited (CNTB) is the stronger overall head-to-head candidate over PolyPid Ltd. (PYPD) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PYPD carries a Unified Composite Score of 31.1/100 (SELL) at $6.43 (N/M Forward P/E, 0.0% operating margin), whereas CNTB carries 41.0/100 (SELL) at $0.61 (0.8x Forward P/E, -2384.5% operating margin).
Defensive Composite Rating Caution: Although CNTB compares more favorably head-to-head, both PYPD (31.1/100 SELL) and CNTB (41.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: PYPD trades in a Markup technical trend (BREAKOUT options phase, RSI 63.2); meanwhile CNTB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PYPD vs CNTB. Trailing 12-month operating profitability (PYPD 0.0% vs CNTB -2384.5%) and valuation multiples (PYPD N/M vs CNTB 0.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $42.6M market capitalization and -2384.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ PYPD vs CNTB Key Questions & Quantitative Answers
As of Nov 17, 2026, Connect Biopharma Holdings Limited (CNTB) is the stronger overall head-to-head candidate over PolyPid Ltd. (PYPD) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PYPD carries a Unified Composite Score of 31.1/100 (SELL) at $6.43 (N/M Forward P/E, 0.0% operating margin), whereas CNTB carries 41.0/100 (SELL) at $0.61 (0.8x Forward P/E, -2384.5% operating margin). Defensive Composite Rating Caution: Although CNTB compares more favorably head-to-head, both PYPD (31.1/100 SELL) and CNTB (41.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: PYPD trades in a Markup technical trend (BREAKOUT options phase, RSI 63.2); meanwhile CNTB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CNTB leads the Growth & Scale pillar: PYPD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CNTB at +5666.7% YoY revenue growth and +0.0% YoY earnings growth on $3.0M TTM revenue (100.0% gross margin, -2384.5% operating margin). On trailing 12-month operating scale, PYPD generates N/A in USD-normalized revenue versus $3.0M for CNTB. In operating R&D and SG&A reinvestment, PYPD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CNTB.
CNTB screens cheaper on headline valuation multiples. PYPD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CNTB trades at 0.8x Forward P/E, 0.8x Trailing P/E, N/M PEG, and 5.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PYPD (-243.6% ROE) versus CNTB (-140.5% ROE) capital efficiency.
In options market volatility and institutional positioning, PYPD carries 106.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.89β · 59% Vol realized risk). By comparison, CNTB carries 397.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.92β · 68% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.